AR095609A1 - Compuestos de pirrolopiridina - Google Patents
Compuestos de pirrolopiridinaInfo
- Publication number
- AR095609A1 AR095609A1 ARP140101234A ARP140101234A AR095609A1 AR 095609 A1 AR095609 A1 AR 095609A1 AR P140101234 A ARP140101234 A AR P140101234A AR P140101234 A ARP140101234 A AR P140101234A AR 095609 A1 AR095609 A1 AR 095609A1
- Authority
- AR
- Argentina
- Prior art keywords
- optionally substituted
- nhc
- alkyl
- nhs
- nrkc
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 9
- 125000003107 substituted aryl group Chemical group 0.000 abstract 6
- 229910052736 halogen Inorganic materials 0.000 abstract 5
- 150000002367 halogens Chemical class 0.000 abstract 5
- 125000001072 heteroaryl group Chemical group 0.000 abstract 5
- 229910052757 nitrogen Inorganic materials 0.000 abstract 5
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 4
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 4
- 229910052799 carbon Inorganic materials 0.000 abstract 3
- 125000005842 heteroatom Chemical group 0.000 abstract 3
- 125000005885 heterocycloalkylalkyl group Chemical group 0.000 abstract 3
- 229910052760 oxygen Inorganic materials 0.000 abstract 3
- 229910052717 sulfur Inorganic materials 0.000 abstract 3
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 2
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 abstract 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 2
- 125000004008 6 membered carbocyclic group Chemical group 0.000 abstract 2
- 125000005330 8 membered heterocyclic group Chemical group 0.000 abstract 2
- 125000003342 alkenyl group Chemical group 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 150000001721 carbon Chemical group 0.000 abstract 2
- 125000000392 cycloalkenyl group Chemical group 0.000 abstract 2
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 abstract 2
- 125000004446 heteroarylalkyl group Chemical group 0.000 abstract 2
- 125000005346 substituted cycloalkyl group Chemical group 0.000 abstract 2
- 125000004434 sulfur atom Chemical group 0.000 abstract 2
- 125000006526 (C1-C2) alkyl group Chemical group 0.000 abstract 1
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 abstract 1
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 abstract 1
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- 125000001931 aliphatic group Chemical group 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 1
- 150000002391 heterocyclic compounds Chemical class 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000002904 solvent Substances 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 125000004426 substituted alkynyl group Chemical group 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/695—Silicon compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
- C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
- C07F7/0814—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring said ring is substituted at a C ring atom by Si
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/10—Compounds having one or more C—Si linkages containing nitrogen having a Si-N linkage
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Compuestos heterocíclicos de fórmula (1), métodos para su preparación, composiciones farmacéuticas que contienen uno de dichos compuestos y sus usos terapéuticos. Reivindicación 1: Un compuesto de la fórmula (1), o una sal, a prodroga, un solvente, un tautómero, un isómero o un análogo deuterado farmacéuticamente aceptable del mismo, en donde: (i) Y² es N e Y³ es C; o (ii) Y² es C e Y³ es N; Y¹ es CH o N; L es un enlace, alquileno C₁₋₆ opcionalmente sustituido, alquileno C₁₋₆ deuterado opcionalmente sustituido, -C(R⁶R⁷)-, -C(O)NR⁹-, -CH₂N(R⁹)-, -SO₂N(R⁹)-, -N(R⁹)C(O)N(R⁹)-, -N(R⁹)SO₂-, -N(R⁹)CH₂-, -O-alquileno C₁₋₄-O-, -alquileno C₁₋₄-O-, -NR⁹C(O)-, -N(R⁹)SO₂-, -C(O)-, -S(O)-, -SO₂-, -O-, -S-, -P(O)(Rᵃ)-, alquileno C₂₋₆ opcionalmente sustituido, -CH=C(Rᵇ)- opcionalmente sustituido o -Si(Rᶜ)(Rᶜ) opcionalmente sustituido; o R⁶ y R⁷ considerados conjuntamente con el átomo de carbono al que se unen forman un anillo de 3 a 6 miembros opcionalmente sustituido que posee entre 0 y 2 heteroátomos a seleccionar a partir de O, N o S o un oxo; Rᵃ es alquilo C₁₋₆ opcionalmente sustituido, arilo opcionalmente sustituido o heteroarilo opcionalmente sustituido; Rᵇ es H o alquilo C₁₋₆; o Rᵇ y R¹ considerados conjuntamente con el átomo de carbono al que se unen forman un anillo carbocíclico de 3 a 6 miembros opcionalmente sustituido o un anillo heterocíclico de 4 a 8 miembros opcionalmente sustituido que posee entre 1 y 2 heteroátomos, como miembros del anillo, a seleccionar a partir de O, N o S, donde los átomos de nitrógeno o azufre del anillo opcionalmente pueden estar oxidados; cada Rᶜ considerado en forma independiente es alquilo C₁₋₆ o alcoxi C₁₋₆; R⁹ es H, alquilo C₁₋₄ o haloalquilo C₁₋₄; R¹, R², R⁴, R⁶ y R⁷ son, considerando cada uno de ellos en forma independiente, H, alquilo C₁₋₆ opcionalmente sustituido, alquenilo C₁₋₆ opcionalmente sustituido, C₁₋₆ alquinilo opcionalmente sustituido, arilo opcionalmente sustituido, heteroarilo opcionalmente sustituido, cicloalquilo opcionalmente sustituido, cicloalquenilo opcionalmente sustituido, heterocicloalquilo opcionalmente sustituido, heterocicloalquilalquilo opcionalmente sustituido, cicloalquilalquilo opcionalmente sustituido, arilo opcionalmente sustituido, heteroarilalquilo opcionalmente sustituido, heterocicloalquilalquilo opcionalmente sustituido-Si(Rᶜ)(Rᶜ) opcionalmente sustituido o R¹³ a seleccionar a partir de halógeno, -CN, -OH, -NH₂, -NO₂, -C(O)OH, -C(S)OH, -C(O)NH₂, -C(S)NH₂, -S(O)₂NH₂, -NHC(O)NH₂, -NHC(S)NH₂, -NHS(O)₂NH₂, -C(NH)NH₂, -CH=C(Rᵍ)(Rᵍ), -ORᵍ, -SRᵍ, -OC(O)Rᵍ, -OC(S)Rᵍ, -P(=O)HRᵍ, -P(=O)RᵍRᵍ, -PH(=O)ORᵍ, -P(=O)(ORᵍ)₂, -OP(=O)(ORᵍ)₂, -C(O)H, -O(CO)ORᵍ, -C(O)Rᵍ, -C(S)Rᵍ, -C(O)ORᵍ, -C(S)ORᵍ, -S(O)Rᵍ, -S(O)₂Rᵍ, -C(O)NHRᵍ, -C(S)NHRᵍ, -C(O)NRᵍRᵍ, -C(S)NRᵍRᵍ, -S(O)₂NHRᵍ, -S(O)₂NRᵍRᵍ, -C(NH)NHRᵍ, -C(NH)NRᵍRᵍ, -NHC(O)Rᵍ, -NHC(S)Rᵍ, -NRᵍC(O)Rᵍ, -NRᵍC(S)Rᵍ, -NHS(O)₂Rᵍ, -NRᵍS(O)₂Rᵍ, -NHC(O)NHRᵍ, -NHC(S)NHRᵍ, -NRᵍC(O)NH₂, -NRᵍC(S)NH₂, -NRᵍC(O)NHRᵍ, -NRᵍC(S)NHRᵍ, -NHC(O)NRᵍRᵍ, -NHC(S)NRᵍRᵍ, -NRᵍC(O)NRᵍRᵍ, -NRᵍC(S)NRᵍRᵍ, -NHS(O)₂NHRᵍ, -NRᵍS(O)₂NH₂, -NRᵍS(O)₂NHRᵍ, -NHS(O)₂NRᵍRᵍ, -NRᵍS(O)₂NRᵍRᵍ, -NHRᵍ o -NRᵍRᵍ, donde cada Rᵍ considerado en forma independiente es H, alquilo C₁₋₆ opcionalmente sustituido, alquenilo C₁₋₆ opcionalmente sustituido, C₁₋₆ alquinilo opcionalmente sustituido, arilo opcionalmente sustituido, heteroarilo opcionalmente sustituido, cicloalquilo opcionalmente sustituido, heterocicloalquilo opcionalmente sustituido heterocicloalquilalquilo, opcionalmente sustituido, cicloalquilalquilo opcionalmente sustituido, aril alquilo opcionalmente sustituido, heteroarilalquilo opcionalmente sustituido o heterocicloalquilalquilo opcionalmente sustituido; o dos Rᵍ grupos cuando están unidos al mismo átomo de carbono o nitrógeno forman, considerados en forma conjunta, un anillo carbocíclico de 3 a 6 miembros o un anillo heterocíclico preferiblemente de 3 a 8 miembros que posee entre 1 y 2 heteroátomos, como miembros del anillo, a seleccionar a partir de O, N o S, donde los átomos de nitrógeno o azufre del anillo opcionalmente están oxidados; donde la porción alifática o aromática de Rᵍ opcionalmente está sustituida con entre 1 y 3 Rʰ sustituyentes a seleccionar, en forma independiente, a partir de halógeno, -CN, -OH, -NH₂, -NO₂, -CH=C(Rⁱ)(Rⁱ), -C(O)OH, -C(S)OH, -C(O)NH₂, -C(S)NH₂, -S(O)₂NH₂, -NHC(O)NH₂, -NHC(S)NH₂, -NHS(O)₂NH₂, -C(NH)NH₂, -ORⁱ-, -SRⁱ, -OC(O)Rⁱ, -OC(S)Rⁱ, -P(=O)HRⁱ, -P(=O)RⁱRⁱ, -PH(=O)ORⁱ, -P(=O)(ORⁱ)₂, -OP(=O)(ORⁱ)₂, -C(O)H, -O(CO)ORⁱ, -C(O)Rⁱ, -C(S)Rⁱ, -C(O)ORⁱ, -C(S)ORⁱ, -S(O)Rⁱ, -S(O)₂Rⁱ, -C(O)NHRⁱ, -C(S)NHRⁱ, -C(O)NRⁱRⁱ, -C(S)NRⁱRⁱ, -S(O)₂NHRⁱ, -S(O)₂NRⁱRⁱ, -C(NH)NHRⁱ, -C(NH)NRⁱRⁱ, -NHC(O)Rⁱ, - NHC(S)Rⁱ, -NRⁱC(O)Rⁱ, -NRⁱC(S)Rⁱ, -NHS(O)₂Rⁱ, -NRⁱS(O)₂Rⁱ, -NHC(O)NHRⁱ, -NHC(S)NHRⁱ, -NRⁱC(O)NH₂, -NRⁱC(S)NH₂, -NRⁱC(O)NHRⁱ, -NRⁱC(S)NHRⁱ, -NHC(O)NRⁱRⁱ, -NHC(S)NRⁱRⁱ ,-NRⁱC(O)NRⁱRⁱ, -NRⁱC(S)NRⁱRⁱ, -NHS(O)₂NHRⁱ, -NRⁱS(O)₂NH₂, -NRⁱS(O)₂NHRⁱ, -NHS(O)₂NRⁱRⁱ, -NRⁱS(O)₂NRⁱRⁱ, Rⁱ, -NHRⁱ o -NRⁱRⁱ, donde cada Rⁱ considerado en forma independiente es alquilo C₁₋₆, arilo, aril-alquilo C₁₋₂, cicloalquilo C₃₋₆, cicloalquil C₃₋₆-alquilo C₁₋₄, heteroarilo, heteroaril-alquilo C₁₋₄, heterocicloalquilo o heterocicloalquil-alquilo C₁₋₄ donde cada Rⁱ a su vez está opcionalmente sustituido con entre 1 y 3 Rᵖ grupos a seleccionar, en forma independiente, a partir de halógeno, CN, -OH, -NH₂, -N(Rq)(Rq), -NO₂, -C(O)OH, -C(O)NH₂, -S(O)₂NH₂, -NHC(O)NH₂, -C(NH)NH₂, -P(=O)HRq, -P(=O)RqRq, -PH(=O)ORq, -P(=O)(ORq)₂, -OP(=O)(ORq)₂, -OC(O)Rq, -OC(S)Rq, -C(O)Rq, -C(S)Rq, -C(O)ORq, -S(O)₂Rq, -C(O)NHRq, alquilo C₁₋₆, alcoxi C₁₋₆, halógeno, haloalquilo C₁₋₆ o haloalcoxi C₁₋₆, donde Rq es alquilo C₁₋₆; R³ es H, halógeno, -CN, alquilo C₁₋₆ opcionalmente sustituido, arilo opcionalmente sustituido, aril-alquilo C₁₋₄ opcionalmente sustituido, heteroarilo opcionalmente sustituido, heteroarilo-alquilo C₁₋₄ opcionalmente sustituido, cicloalquilo C₃₋₈ opcionalmente sustituido, cicloalquenilo C₃₋₈ opcionalmente sustituido, cicloalquil C₃₋₈-alquilo C₁₋₄ opcionalmente sustituido, alquinilo C₂₋₆ opcionalmente sustituido, heterocicloalquilo opcionalmente sustituido, heterocicloalquil-alquilo C₁₋₄ opcionalmente sustituido o Rʲ a seleccionar a partir de halógeno, -CN, -OH, -NH₂, -NO₂, -C(O)OH, -C(S)OH, -C(O)NH₂, -C(S)NH₂, -S(O)₂NH₂, -NHC(O)NH₂, -NHC(S)NH₂, -NHS(O)₂NH₂, -C(NH)NH₂, -CH=C(Rᵏ)(Rᵏ), -ORᵏ, -SRᵏ, -OC(O)Rᵏ, -OC(S)Rᵏ, -P(=O)HRᵏ, -P(=O)RᵏRᵏ, -PH(=O)ORᵏ, -P(=O)(ORᵏ)₂, -OP(=O)(ORᵏ)₂, -C(O)H, -O(CO)ORᵏ, -C(O)Rᵏ, -C(S)Rᵏ, -C(O)ORᵏ, -C(S)ORᵏ, -S(O)Rᵏ, -S(O)₂Rᵏ, -C(O)NHRᵏ, -C(S)NHRᵏ, -C(O)NRᵏRᵏ, -C(S)NRᵏRᵏ, -S(O)₂NHRᵏ, -S(O)₂NRᵏRᵏ, -C(NH)NHRᵏ, -C(NH)NRᵏRᵏ, -NHC(O)Rᵏ, -NHC(S)Rᵏ, -NRᵏC(O)Rᵏ, -NRᵏC(S)Rᵏ, -NHS(O)₂Rᵏ, -NRᵏS(O)₂Rᵏ, -NHC(O)NHRᵏ, -NHC(S)NHRᵏ, -NRᵏC(O)NH₂, -NRᵏC(S)NH₂, -NRᵏC(O)NHRᵏ, -NRᵏC(S)NHRᵏ, -NHC(O)NRᵏRᵏ, -NHC(S)NRᵏRᵏ, -NRᵏC(O)NRᵏRᵏ, -NRᵏC(S)NRᵏRᵏ, -NHS(O)₂NHRᵏ, -NRᵏS(O)₂NH₂, -NRᵏS(O)₂NHRᵏ, -NHS(O)₂NRᵏRᵏ,
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361798856P | 2013-03-15 | 2013-03-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR095609A1 true AR095609A1 (es) | 2015-10-28 |
Family
ID=51654873
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP140101234A AR095609A1 (es) | 2013-03-15 | 2014-03-17 | Compuestos de pirrolopiridina |
Country Status (2)
Country | Link |
---|---|
US (3) | US20140303121A1 (es) |
AR (1) | AR095609A1 (es) |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008063888A2 (en) | 2006-11-22 | 2008-05-29 | Plexxikon, Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
CN101808994B (zh) | 2007-07-17 | 2013-05-15 | 普莱希科公司 | 用于激酶调节的化合物和方法以及其适应症 |
WO2009143018A2 (en) | 2008-05-19 | 2009-11-26 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
MY156210A (en) | 2009-11-18 | 2016-01-29 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
BR112012015745A2 (pt) | 2009-12-23 | 2016-05-17 | Plexxikon Inc | compostos e métodos para a modulação de quinase, e indicações dos mesmos |
TWI510487B (zh) | 2010-04-21 | 2015-12-01 | Plexxikon Inc | 用於激酶調節的化合物和方法及其適應症 |
AU2012214762B2 (en) | 2011-02-07 | 2015-08-13 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
BR112013029163A2 (pt) | 2011-05-17 | 2017-01-31 | Plexxikon Inc | modulação quinase e indicações dos mesmos |
US9358235B2 (en) | 2012-03-19 | 2016-06-07 | Plexxikon Inc. | Kinase modulation, and indications therefor |
US9150570B2 (en) | 2012-05-31 | 2015-10-06 | Plexxikon Inc. | Synthesis of heterocyclic compounds |
JP6318156B2 (ja) | 2012-09-06 | 2018-04-25 | プレキシコン インコーポレーテッドPlexxikon Inc. | キナーゼをモジュレートするための化合物および方法、ならびにその指標 |
WO2014080290A2 (en) | 2012-11-21 | 2014-05-30 | Rvx Therapeutics Inc. | Cyclic amines as bromodomain inhibitors |
WO2014080291A2 (en) | 2012-11-21 | 2014-05-30 | Rvx Therapeutics Inc. | Biaryl derivatives as bromodomain inhibitors |
US9676748B2 (en) | 2012-12-21 | 2017-06-13 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
WO2014096965A2 (en) | 2012-12-21 | 2014-06-26 | Rvx Therapeutics Inc. | Novel heterocyclic compounds as bromodomain inhibitors |
US20140303121A1 (en) | 2013-03-15 | 2014-10-09 | Plexxikon Inc. | Heterocyclic compounds and uses thereof |
JP6325078B2 (ja) | 2013-03-15 | 2018-05-16 | プレキシコン インコーポレーテッドPlexxikon Inc. | ヘテロ環式化合物およびその使用 |
EP3004060B1 (en) | 2013-05-30 | 2019-11-27 | Plexxikon Inc. | Compounds for kinase modulation, and indications therefor |
CN104230922B (zh) * | 2013-06-19 | 2016-12-28 | 中国科学院上海药物研究所 | 一类五元杂环并吡啶类化合物及其制备方法和用途 |
JP6461118B2 (ja) | 2013-06-21 | 2019-01-30 | ゼニス・エピジェネティクス・リミテッドZenith Epigenetics Ltd. | ブロモドメイン阻害剤としての新規の置換された二環式化合物 |
SI3010503T1 (sl) | 2013-06-21 | 2020-07-31 | Zenith Epigenetics Ltd. | Novi biciklični inhibitorji bromodomene |
KR20160038008A (ko) | 2013-07-31 | 2016-04-06 | 제니쓰 에피제네틱스 코포레이션 | 브로모도메인 억제제로서 신규 퀴나졸리논 |
WO2015134536A1 (en) | 2014-03-04 | 2015-09-11 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
JP6832846B2 (ja) | 2014-09-15 | 2021-02-24 | プレキシコン インコーポレーテッドPlexxikon Inc. | ヘテロ環化合物およびその用途 |
CA2966303A1 (en) | 2014-12-01 | 2016-06-09 | Zenith Epigenetics Ltd. | Substituted pyridines as bromodomain inhibitors |
CA2966298A1 (en) | 2014-12-01 | 2016-06-09 | Zenith Epigenetics Ltd. | Substituted pyridinones as bromodomain inhibitors |
EP3230277B1 (en) | 2014-12-11 | 2019-09-18 | Zenith Epigenetics Ltd. | Substituted heterocycles as bromodomain inhibitors |
EP3233846A4 (en) | 2014-12-17 | 2018-07-18 | Zenith Epigenetics Ltd. | Inhibitors of bromodomains |
US10160755B2 (en) | 2015-04-08 | 2018-12-25 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
US9745298B2 (en) | 2015-05-06 | 2017-08-29 | Plexxikon Inc. | Synthesis of a compound that modulates kinases |
MX2017013975A (es) | 2015-05-06 | 2018-01-16 | Plexxikon Inc | Formas solidas de quinasas que modulan un compuesto. |
WO2016191296A1 (en) | 2015-05-22 | 2016-12-01 | Plexxikon Inc. | Plx-8394 or plx-7904 for use in the treatment of braf-v600-related diseases |
CA2986735A1 (en) | 2015-05-22 | 2016-12-01 | Plexxikon Inc. | Solid forms of a compound for modulating kinases |
WO2017019804A2 (en) | 2015-07-28 | 2017-02-02 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
CN113754656A (zh) | 2015-09-21 | 2021-12-07 | 普莱希科公司 | 杂环化合物及其应用 |
BR112018011475A2 (pt) | 2015-12-07 | 2018-12-04 | Plexxikon Inc | compostos e métodos para modulação de quinase e indicação para a mesma |
CN108602821B (zh) * | 2015-12-14 | 2021-06-29 | 恒元生物医药科技(苏州)有限公司 | 1h-咪唑并[4,5-b]吡啶基bet溴结构域抑制剂 |
US10160747B2 (en) | 2016-03-16 | 2018-12-25 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
TW201815766A (zh) | 2016-09-22 | 2018-05-01 | 美商普雷辛肯公司 | 用於ido及tdo調節之化合物及方法以及其適應症 |
AU2017395023B2 (en) | 2016-12-23 | 2022-04-07 | Plexxikon Inc. | Compounds and methods for CDK8 modulation and indications therefor |
AU2018237047A1 (en) | 2017-03-20 | 2019-10-17 | Plexxikon Inc. | Crystalline forms of 4-(1-(1,1-di(pyridin-2-yl)ethyl)-6-(3,5-dimethylisoxazol-4-yl)-1H- pyrrolo[3,2-b]pyridin-3-yl)benzoic acid that inhibits bromodomain |
WO2018226846A1 (en) | 2017-06-07 | 2018-12-13 | Plexxikon Inc. | Compounds and methods for kinase modulation |
TWI805599B (zh) | 2017-07-25 | 2023-06-21 | 美商第一三共公司 | 激酶調節化合物之調配物 |
EP3694855A1 (en) | 2017-10-13 | 2020-08-19 | Plexxikon Inc. | Solid forms of a compound for modulating kinases |
CN112165958A (zh) | 2017-10-27 | 2021-01-01 | 普莱希科公司 | 调制激酶的化合物的制剂 |
CN112119072A (zh) | 2018-03-20 | 2020-12-22 | 普莱希科公司 | 用于ido和tdo调节的化合物和方法,以及其适应症 |
CN113710668A (zh) | 2019-04-09 | 2021-11-26 | 普莱希科公司 | 用于ep300或cbp调节及其适应症的缩合吖嗪 |
US11807626B2 (en) | 2020-04-23 | 2023-11-07 | Opna Bio SA | Compounds and methods for CD73 modulation and indications therefor |
CN116322690A (zh) | 2020-08-21 | 2023-06-23 | 奥普纳生物有限公司 | 组合的药物抗癌疗法 |
Family Cites Families (111)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5317103A (en) | 1991-01-15 | 1994-05-31 | Merck Sharp & Dohme Limited | Indole-substituted five-membered heteroaromatic compounds as 5-HT1 agonists |
US5998438A (en) | 1996-11-26 | 1999-12-07 | Allelix Biopharmaceuticals, Inc. | 5-cyclo indole compounds |
KR100378937B1 (ko) * | 1997-10-20 | 2003-05-09 | 에프. 호프만-라 로슈 아게 | 바이사이클릭 키나아제 억제제 |
US6358992B1 (en) | 1998-11-25 | 2002-03-19 | Cell Pathways, Inc. | Method of inhibiting neoplastic cells with indole derivatives |
US6281356B1 (en) | 1999-12-22 | 2001-08-28 | Hoffmann-La Roche Inc. | Substituted pyrroles |
SK288019B6 (sk) | 1999-12-24 | 2012-11-05 | Aventis Pharma Limited | Azaindoles derivatives, their use and pharmaceutical composition containing thereof |
GB0031315D0 (en) | 2000-12-21 | 2001-02-07 | Glaxo Group Ltd | Indole derivatives |
US20040110785A1 (en) * | 2001-02-02 | 2004-06-10 | Tao Wang | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives |
EP1314733A1 (en) | 2001-11-22 | 2003-05-28 | Aventis Pharma Deutschland GmbH | Indole-2-carboxamides as factor Xa inhibitors |
US20040171062A1 (en) | 2002-02-28 | 2004-09-02 | Plexxikon, Inc. | Methods for the design of molecular scaffolds and ligands |
KR20050013534A (ko) | 2002-03-28 | 2005-02-04 | 에자이 가부시키가이샤 | c─Jun N─말단 키나아제 억제용 아자인돌 |
ATE482938T1 (de) | 2002-08-09 | 2010-10-15 | Merck Sharp & Dohme | Tyrosinkinaseinhibitoren |
CA2503905A1 (en) | 2002-09-16 | 2004-03-25 | Plexxikon, Inc. | Crystal structure of pim-1 kinase |
US20050048573A1 (en) | 2003-02-03 | 2005-03-03 | Plexxikon, Inc. | PDE5A crystal structure and uses |
US20040167188A1 (en) * | 2003-02-14 | 2004-08-26 | Zhili Xin | Protein-tyrosine phosphatase inhibitors and uses thereof |
JP2007524374A (ja) | 2003-02-28 | 2007-08-30 | プレキシコン,インコーポレーテッド | Pyk2結晶構造および使用 |
EP1599475A2 (en) * | 2003-03-06 | 2005-11-30 | Eisai Co., Ltd. | Jnk inhibitors |
SE0301569D0 (sv) | 2003-05-27 | 2003-05-27 | Astrazeneca Ab | Novel compounds |
US20050079548A1 (en) | 2003-07-07 | 2005-04-14 | Plexxikon, Inc. | Ligand development using PDE4B crystal structures |
US7348338B2 (en) | 2003-07-17 | 2008-03-25 | Plexxikon, Inc. | PPAR active compounds |
WO2005009958A1 (en) | 2003-07-17 | 2005-02-03 | Plexxikon, Inc. | Ppar active compounds |
US20050164300A1 (en) | 2003-09-15 | 2005-07-28 | Plexxikon, Inc. | Molecular scaffolds for kinase ligand development |
US7517970B2 (en) | 2003-12-19 | 2009-04-14 | Plexxikon, Inc. | Nucleic acids encoding kinase and phosphatase enzymes, expression vectors and cells containing same |
US7504509B2 (en) | 2003-12-19 | 2009-03-17 | Plexxikon, Inc. | Compounds and methods for development of Ret modulators |
US20070066641A1 (en) | 2003-12-19 | 2007-03-22 | Prabha Ibrahim | Compounds and methods for development of RET modulators |
CN101031293A (zh) | 2004-05-06 | 2007-09-05 | 普莱希科公司 | Pde4b抑制剂及其应用 |
US7498342B2 (en) | 2004-06-17 | 2009-03-03 | Plexxikon, Inc. | Compounds modulating c-kit activity |
WO2006009755A2 (en) | 2004-06-17 | 2006-01-26 | Plexxikon, Inc. | Azaindoles modulating c-kit activity and uses therefor |
EP2264033A1 (en) | 2004-07-27 | 2010-12-22 | SGX Pharmaceuticals, Inc. | 3,5-DIPHENYL-SUBSTITUTED PYRROLO[2,3b]PYRIDINES USEFUL AS KINASE INHIBITORS |
CN101048407A (zh) | 2004-09-03 | 2007-10-03 | 普莱希科公司 | 双环杂芳基pde4b抑制剂 |
CA2588953A1 (en) | 2004-11-30 | 2006-06-08 | Plexxikon, Inc. | Ppar active compounds |
US20060135540A1 (en) | 2004-11-30 | 2006-06-22 | Jack Lin | PPAR active compounds |
US20060160135A1 (en) | 2004-12-08 | 2006-07-20 | Weiru Wang | SF-1 and LRH-1 modulator development |
US20060183758A1 (en) | 2005-02-17 | 2006-08-17 | Cb Research And Development, Inc. | Method for synthesis of AZA-annelated pyrroles, thiophenes, and furans |
EP1885723A2 (en) | 2005-05-17 | 2008-02-13 | Plexxikon, Inc. | Pyrrolo[2,3-b]pyridine derivatives as protein kinase inhibitors |
WO2007002433A1 (en) | 2005-06-22 | 2007-01-04 | Plexxikon, Inc. | Pyrrolo [2, 3-b] pyridine derivatives as protein kinase inhibitors |
ES2372701T3 (es) | 2005-07-22 | 2012-01-25 | Shionogi & Co., Ltd. | Derivado de indol que tiene actividad antagonista del receptor de pgd2. |
JP2009507079A (ja) | 2005-09-07 | 2009-02-19 | プレキシコン,インコーポレーテッド | Ppar活性化合物 |
TW200800872A (en) | 2005-09-07 | 2008-01-01 | Plexxikon Inc | PPAR active compounds |
CA2621275A1 (en) | 2005-09-07 | 2007-03-15 | Plexxikon, Inc. | 1 , 4 and 1 , 5-disubstituted indole derivatives for use as ppar active compounds |
JP2010519171A (ja) * | 2006-02-17 | 2010-06-03 | メモリー・ファーマシューティカルズ・コーポレイション | 5−ht6受容体親和性を有する化合物 |
BRPI0717317A2 (pt) * | 2006-10-23 | 2013-10-22 | Sgx Pharmaceuticals Inc | Modularoes da proteína cinase triazalopiridazina |
WO2008063888A2 (en) | 2006-11-22 | 2008-05-29 | Plexxikon, Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
WO2008079909A1 (en) | 2006-12-21 | 2008-07-03 | Plexxikon, Inc. | Pyrrolo [2,3-b] pyridines as kinase modulators |
PE20121126A1 (es) | 2006-12-21 | 2012-08-24 | Plexxikon Inc | Compuestos pirrolo [2,3-b] piridinas como moduladores de quinasa |
EP2094701A2 (en) | 2006-12-21 | 2009-09-02 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
US8524917B2 (en) | 2007-01-11 | 2013-09-03 | Allergan, Inc. | 6-substituted indole-3-carboxylic acid amide compounds having sphingosine-1-phosphate (S1P) receptor antagonist biological activity |
US8193237B2 (en) | 2007-01-15 | 2012-06-05 | Santen Pharmaceutical Co., Ltd. | Indole derivative having IκB kinase β inhibitory activity |
MX2009008439A (es) | 2007-02-12 | 2009-08-13 | Intermune Inc | Nuevos inhibidores de la replicacion del virus de hepatitis c. |
AU2008222807A1 (en) | 2007-03-08 | 2008-09-12 | Plexxikon, Inc. | PPAR active compounds |
PE20090159A1 (es) | 2007-03-08 | 2009-02-21 | Plexxikon Inc | COMPUESTOS DERIVADOS DE ACIDO INDOL-PROPIONICO COMO MODULADORES PPARs |
WO2008110508A1 (en) | 2007-03-09 | 2008-09-18 | Glaxo Group Limited | Pyrrolo-pyridine derivatives for the treatment of disorders associated with inappropriate ikk1 activity |
DE102007028515A1 (de) | 2007-06-21 | 2008-12-24 | Merck Patent Gmbh | 6-(Pyrrolopyridinyl)-pyrimidinyl-2-amin-derivate |
CN101808994B (zh) | 2007-07-17 | 2013-05-15 | 普莱希科公司 | 用于激酶调节的化合物和方法以及其适应症 |
CA2695114A1 (en) | 2007-08-01 | 2009-02-05 | Pfizer Inc. | Pyrazole compounds and their use as raf inhibitors |
WO2009143018A2 (en) | 2008-05-19 | 2009-11-26 | Plexxikon, Inc. | Compounds and methods for kinase modulation, and indications therefor |
PE20091846A1 (es) | 2008-05-19 | 2009-12-16 | Plexxikon Inc | DERIVADOS DE PIRROLO[2,3-d]-PIRIMIDINA COMO MODULADORES DE CINASAS |
US20090298820A1 (en) * | 2008-05-28 | 2009-12-03 | Wyeth | 3-substituted-1h-pyrrolo[2,3-b]pyridine and 3-substituted-1h-pyrrolo[3,2-b]pyridine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses |
US8110576B2 (en) | 2008-06-10 | 2012-02-07 | Plexxikon Inc. | Substituted pyrrolo[2,3b]pyrazines and methods for treatment of raf protein kinase-mediated indications |
AU2009257635A1 (en) | 2008-06-10 | 2009-12-17 | Plexxikon, Inc. | 5H-Pyrrolo [2,3-b] pyrazine derivatives for kinase modulation, and indications therefor |
AR072008A1 (es) | 2008-06-13 | 2010-07-28 | Merck & Co Inc | Compuestos heterobiciclicos como agentes de inhibicion de quinasa p38 |
US8012992B2 (en) | 2008-06-30 | 2011-09-06 | Allergan, Inc. | Aza-indoles and related compounds having sphingosine-1-phosphate (S1P) receptor antagonist biological activity |
DE102008031517A1 (de) | 2008-07-03 | 2010-01-07 | Merck Patent Gmbh | Pyrrolopyridinyl-pyrimidin-2-yl-amin-derivate |
US8912330B2 (en) * | 2008-12-12 | 2014-12-16 | Ariad Pharmaceuticals, Inc. | Azaindole derivatives as kinase inhibitors |
EP2406259A1 (en) | 2009-03-11 | 2012-01-18 | Plexxikon, Inc. | Pyrrolo [2, 3-b]pyridine derivatives for the inhibition of raf kinases |
CN102421775A (zh) | 2009-03-11 | 2012-04-18 | 普莱希科公司 | 抑制Raf激酶的吡咯并[2,3-b]吡啶衍生物 |
WO2010111527A1 (en) | 2009-03-26 | 2010-09-30 | Plexxikon, Inc. | Pyrazolo [ 3, 4 -b] pyridines as kinase inhibitors and their medical use |
US9447089B2 (en) | 2009-04-03 | 2016-09-20 | Plexxikon Inc. | Compositions and uses thereof |
SG175877A1 (en) | 2009-05-04 | 2011-12-29 | Plexxikon Inc | Compounds and methods for inhibition of renin, and indications therefor |
TW201041888A (en) | 2009-05-06 | 2010-12-01 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
KR101256018B1 (ko) | 2009-08-20 | 2013-04-18 | 한국과학기술연구원 | 단백질 키나아제 저해활성을 갖는 1,3,6-치환된 인돌 화합물 |
UA105813C2 (uk) | 2009-11-06 | 2014-06-25 | Плексікон, Інк. | Сполуки-інгібітори кіназ та фармацевтична композиція (варіанти) |
MY156210A (en) | 2009-11-18 | 2016-01-29 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
BR112012015745A2 (pt) | 2009-12-23 | 2016-05-17 | Plexxikon Inc | compostos e métodos para a modulação de quinase, e indicações dos mesmos |
TWI510487B (zh) | 2010-04-21 | 2015-12-01 | Plexxikon Inc | 用於激酶調節的化合物和方法及其適應症 |
AR081039A1 (es) | 2010-05-14 | 2012-05-30 | Osi Pharmaceuticals Llc | Inhibidores biciclicos fusionados de quinasa |
US8642606B2 (en) | 2010-09-29 | 2014-02-04 | Plexxikon Inc. | ZAP-70 active compounds |
AU2011333472A1 (en) | 2010-11-26 | 2013-06-06 | Lupin Limited | Bicyclic GPR119 modulators |
DE102011009961A1 (de) | 2011-02-01 | 2012-08-02 | Merck Patent Gmbh | 7-Azaindolderivate |
AU2012214762B2 (en) | 2011-02-07 | 2015-08-13 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
TWI558702B (zh) | 2011-02-21 | 2016-11-21 | 普雷辛肯公司 | 醫藥活性物質的固態形式 |
BR112013029163A2 (pt) | 2011-05-17 | 2017-01-31 | Plexxikon Inc | modulação quinase e indicações dos mesmos |
AR089653A1 (es) | 2011-10-25 | 2014-09-10 | Shionogi & Co | Derivados heterociclicos que tienen actividad antagonista del receptor de pgd2 |
WO2013078254A1 (en) | 2011-11-22 | 2013-05-30 | Array Biopharma Inc. | Bicyclic heteroaryl derivatives as kinase inhibitors |
FR2984325A1 (fr) | 2011-12-14 | 2013-06-21 | Sanofi Sa | Derives de pyrazolopyridine, leur procede de preparation et leur application en therapeutique |
US20130158066A1 (en) | 2011-12-20 | 2013-06-20 | Hoffmann-La Roche Inc. | 4-azaindole inhibitors of crac |
US9358235B2 (en) | 2012-03-19 | 2016-06-07 | Plexxikon Inc. | Kinase modulation, and indications therefor |
US9150570B2 (en) | 2012-05-31 | 2015-10-06 | Plexxikon Inc. | Synthesis of heterocyclic compounds |
JP6318156B2 (ja) | 2012-09-06 | 2018-04-25 | プレキシコン インコーポレーテッドPlexxikon Inc. | キナーゼをモジュレートするための化合物および方法、ならびにその指標 |
US9676748B2 (en) | 2012-12-21 | 2017-06-13 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
US20140303121A1 (en) | 2013-03-15 | 2014-10-09 | Plexxikon Inc. | Heterocyclic compounds and uses thereof |
JP6325078B2 (ja) | 2013-03-15 | 2018-05-16 | プレキシコン インコーポレーテッドPlexxikon Inc. | ヘテロ環式化合物およびその使用 |
EP3004060B1 (en) | 2013-05-30 | 2019-11-27 | Plexxikon Inc. | Compounds for kinase modulation, and indications therefor |
JP6461118B2 (ja) | 2013-06-21 | 2019-01-30 | ゼニス・エピジェネティクス・リミテッドZenith Epigenetics Ltd. | ブロモドメイン阻害剤としての新規の置換された二環式化合物 |
SI3010503T1 (sl) | 2013-06-21 | 2020-07-31 | Zenith Epigenetics Ltd. | Novi biciklični inhibitorji bromodomene |
WO2015134536A1 (en) | 2014-03-04 | 2015-09-11 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
JP6832846B2 (ja) | 2014-09-15 | 2021-02-24 | プレキシコン インコーポレーテッドPlexxikon Inc. | ヘテロ環化合物およびその用途 |
US10160755B2 (en) | 2015-04-08 | 2018-12-25 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
US9745298B2 (en) | 2015-05-06 | 2017-08-29 | Plexxikon Inc. | Synthesis of a compound that modulates kinases |
MX2017013975A (es) | 2015-05-06 | 2018-01-16 | Plexxikon Inc | Formas solidas de quinasas que modulan un compuesto. |
WO2016191296A1 (en) | 2015-05-22 | 2016-12-01 | Plexxikon Inc. | Plx-8394 or plx-7904 for use in the treatment of braf-v600-related diseases |
CA2986735A1 (en) | 2015-05-22 | 2016-12-01 | Plexxikon Inc. | Solid forms of a compound for modulating kinases |
WO2017019804A2 (en) | 2015-07-28 | 2017-02-02 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
CN113754656A (zh) | 2015-09-21 | 2021-12-07 | 普莱希科公司 | 杂环化合物及其应用 |
BR112018011475A2 (pt) | 2015-12-07 | 2018-12-04 | Plexxikon Inc | compostos e métodos para modulação de quinase e indicação para a mesma |
US10160747B2 (en) | 2016-03-16 | 2018-12-25 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
TW201815766A (zh) | 2016-09-22 | 2018-05-01 | 美商普雷辛肯公司 | 用於ido及tdo調節之化合物及方法以及其適應症 |
AU2017395023B2 (en) | 2016-12-23 | 2022-04-07 | Plexxikon Inc. | Compounds and methods for CDK8 modulation and indications therefor |
AU2018237047A1 (en) | 2017-03-20 | 2019-10-17 | Plexxikon Inc. | Crystalline forms of 4-(1-(1,1-di(pyridin-2-yl)ethyl)-6-(3,5-dimethylisoxazol-4-yl)-1H- pyrrolo[3,2-b]pyridin-3-yl)benzoic acid that inhibits bromodomain |
EP3694855A1 (en) | 2017-10-13 | 2020-08-19 | Plexxikon Inc. | Solid forms of a compound for modulating kinases |
CN112165958A (zh) | 2017-10-27 | 2021-01-01 | 普莱希科公司 | 调制激酶的化合物的制剂 |
-
2014
- 2014-03-14 US US14/213,734 patent/US20140303121A1/en not_active Abandoned
- 2014-03-17 AR ARP140101234A patent/AR095609A1/es unknown
-
2015
- 2015-09-04 US US14/846,545 patent/US9822109B2/en active Active
-
2017
- 2017-11-15 US US15/814,179 patent/US10501460B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US20180072722A1 (en) | 2018-03-15 |
US20140303121A1 (en) | 2014-10-09 |
US9822109B2 (en) | 2017-11-21 |
US20160068528A1 (en) | 2016-03-10 |
US10501460B2 (en) | 2019-12-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR095609A1 (es) | Compuestos de pirrolopiridina | |
AR105820A1 (es) | Análogos de nucleósidos sustituidos en el anillo aromático bicíclico 6-6 para su uso como inhibidores de prmt5 | |
AR104176A1 (es) | Inhibidores de ido (indolamina-2,3-dioxigenasa) | |
AR096979A1 (es) | Derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
AR091193A1 (es) | HETEROCICLOS DE 5 MIEMBROS QUE CONTIENEN NITROGENO SUSTITUIDO POR CARBOXAMIDA O SULFONAMIDA COMO MODULADORES PARA EL RECEPTOR NUCLEAR HUERFANO RORg | |
AR106595A1 (es) | COMPUESTOS HETEROCÍCLICOS COMO INHIBIDORES DE PI3K-g | |
AR092108A1 (es) | Piridazina 1,4 disustituida, analogos de la misma y metodos para tratar las enfermedades relacionadas con deficiencia del smn | |
AR095426A1 (es) | Inhibidores tripeptídicos de la epoxicetona proteasa | |
AR106763A1 (es) | Oxadiazoles sustituidos para combatir hongos fitopatógenos | |
AR102177A1 (es) | Compuestos de heteroarilo como inhibidores de btk y usos de los mismos | |
AR098136A1 (es) | Compuestos de heteroarilo como inhibidores de btk y usos de los mismos | |
AR103138A1 (es) | Compuestos de heteroarilo como inhibidores de la irak y usos de los mismos | |
AR094300A1 (es) | Derivados de quinolonas | |
AR103252A1 (es) | Compuestos de quinazolina | |
AR101174A1 (es) | Imidazopirazinas como inhibidores de lsd1 | |
PE20160678A1 (es) | Inhibidores marcados de antigeno prostatico especifico de membrana (psma), su uso como agentes formadores de imagenes y agentes farmaceuticos para el tratamiento de cancer de prostata | |
AR089143A1 (es) | Triazolopiridinas sustituidas con actividad inhibidora de ttk | |
AR088828A1 (es) | DERIVADOS DE CICLOHEXILAMINA QUE TIENEN ACTIVIDAD COMO AGONISTAS ADRENERGICOS b2 Y COMO ANTAGONISTAS MUSCARINICOS M3 | |
AR098432A1 (es) | Compuestos heterocíclicos | |
AR105893A1 (es) | Derivados del anillo (hetero) aromático sustituidos con carboxi como inhibidores de xantina oxidasa y del transportador 1 del anión urato | |
AR103598A1 (es) | Ácidos bicíclicos[4,6,0]hidroxámicos como inhibidores de hdac | |
AR101528A1 (es) | Inhibidores de cdk9 quinasa de pirrolo[2,3-b]piridina | |
AR097755A1 (es) | Derivados sustituidos de fenilalanina como moduladores del factor xia | |
AR089814A1 (es) | Compuestos que modulan la actividad de los proteasomas | |
AR101964A1 (es) | Compuestos de imidazopiridazina como moduladores de pi3k |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |